Huahai pharmaceutical's production approval of class 3.1 new anti gout drug, non Brest, has been accepted

According to the information on June 4 on the website of the State Food and Drug Administration (CFDA), the approval documents for the production of non brescial APIs and tablets for class 3.1 chemical drugs declared by Huahai pharmaceutical were accepted Febuxta is a new anti gout drug, which was successfully developed by Japanese Imperial pharmaceutical In 2008 and 2009, it was approved by the European Union and FDA In 2010, the annual sales of the product reached 1.2 billion US dollars According to CFDA, there are currently three domestic enterprises approved to produce the drug preparation last year They are: Hangzhou zhuyangxin Pharmaceutical Co., Ltd., a subsidiary of Huadong Pharmaceutical Group, Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd., a holding subsidiary of Fosun Pharmaceutical (600196 SH), and Hengrui Pharmaceutical (600276 SH) In addition to Huahai Pharmaceutical Co., Ltd., there are four other enterprises, i.e Sinopharm group and Zhuhai Federation, which are also applying for production.